NCT06890338 (ClinicalTrials.gov Identifier: NCT06890338) is a Phase 2 clinical trial evaluating the combination of an investigational antibody-drug conjugate, mirvetuximab soravtansine (also known as MIRV or ELAHERE™), administered intravenously, with carboplatin, administered intravenously, in adult female patients with newly diagnosed FRα-expressing advanced-stage (FIGO Stage III-IV) serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. The trial is part of a multicenter research effort.

The study is designed to assess the safety and anti-tumor activity of this investigational combination therapy as neoadjuvant treatment, with all treatment approaches being studied for research purposes in accordance with the approved study protocol.

“OSF HealthCare remains deeply committed to advancing oncology research tailored to gynecologic malignancies, including the challenges of advanced-stage ovarian cancer, through strategic collaborations with innovative partners to bring promising clinical trials directly to our patients,” said Dr. Michelle Rowland, Translational Researcher and Gynecologic Oncologist, OSF HealthCare Cancer Institute. “Participating in these important studies allows us to provide eligible patients facing newly diagnosed advanced ovarian cancer with potential access to novel investigational therapies that address significant unmet needs in managing this disease.”

All clinical research conducted at OSF HealthCare undergoes rigorous review and ongoing oversight to help ensure patient safety and ethical conduct.

Patients interested in learning more about clinical research at OSF HealthCare are encouraged to speak with their care team, call (844) 673-4467 or email sfmc.clinicaltrials@osfhealthcare.org.